“It’s an exciting time at Augmenix,” said John Pedersen, Augmenix CEO. “Just months after our published clinical study results and FDA clearance, accelerated acceptance of the SpaceOAR System by leading radiotherapy centers across the country speaks to the fact that the technology fills an important need in the market. Given the strong clinical evidence and the recent momentum, we anticipate a high level of interest from clinicians and industry at the upcoming ASTRO meeting and look forward to showcasing the SpaceOAR technology at this important industry event.”
Augmenix will showcase the SpaceOAR System in booth #508 and is sponsoring an Industry Expert Theater, which will take place on Monday, October 19 at 12:30 p.m. The symposium presentation will include:
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
• Dr. John Sylvester, radiation oncologist at 21st Century Oncology, who will present the SpaceOAR U.S. Pivotal study results;
• Dr. Marcio Fagundes, medical director at Provision Center for Proton Therapy, who will discuss spacer use in proton radiotherapy;
• and Dr. Robert Timmerman, professor and vice chair of the Department of Radiation Oncology and Professor of Neurosurgery at UT Southwestern, who will discuss spacer use in dose escalated SBRT.
The Augmenix Products
Using a minimally invasive procedure, the SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy and then liquefies and is completely absorbed. The SpaceOAR System is FDA cleared, CE marked and TGA approved. Augmenix also markets TraceIT® Hydrogel, the world’s first absorbable hydrogel tissue marker with CT, MRI and ultrasound visibility. TraceIT Hydrogel is FDA cleared and CE marked for use throughout the body, and is finding utility as a marker to improve radiation targeting of tumors. See the SpaceOAR System and TraceIT Tissue Marker IFUs for complete information regarding potential risks, complications and warnings.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.
Back to HCB News
